Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Approval Alert: AstraZeneca/Sanofi’s Beyfortus® (nirsevimab) to Prevent RSV LRTD Approved by NMPA

Jan 2, 2024

AstraZeneca and Sanofi announced that Beyfortus® (nirsevimab) has been approved by the National Medical Products Administration (NMPA) in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season.  The companies anticipate Beyfortus® will be available during the upcoming 2024-2025 RSV season.  Beyfortus® is the first approved preventive option to protect against RSV in a broad infant population.

The FDA approved Beyfortus® for the same indication and to treat children up to two years old who are vulnerable to severe RSV disease through their second RSV season on 17 July 2023.